Ally Biotech has announced the acquisition of the Chill Pill brand, a popular line of soft gel capsules, in an all-cash transaction. The Chill Pill brand was founded in 2018 and quickly became dominant in its product category for both medical and adult use consumers, and is now distributed in nearly 40 licensed dispensaries in Arizona. Ally Biotech is a cannabis science company that develops and provides bioactive cannabinoid delivery solutions, with a proprietary nano-liposomal technology that provides effective and increased absorption on the cellular level. The company plans to expand the Chill Pill line to include new products developed with highly bioavailable custom formulations.
Ally Biotech, a science-based company and provider of leading-edge bioactive cannabinoid delivery solutions, today announced the acquisition of the popular Chill Pill™ brand, an extensive line of soft, easy-to-swallow soft gel caps and all of its assets, from Desert Medical Campus, in an all-cash transaction.
The Chill Pill brand, founded in 2018 by Andrew Provencio at his Desert Medical Campus facility, offered the first THC soft gel cap on the market in Arizona. The product quickly gained dominance within its product category for both medical and adult use consumers, which it still maintains. The Chill Pill line is now distributed in nearly 40 licensed Arizona dispensaries.
Ally Biotech is the cannabis science company behind the Lipofusion® delivery technology, considered the next generation of oral delivery technologies for the cannabinoid market. Their proprietary nano-liposomal technology protects bio-actives from degradation in the digestive system and provides effective and increased absorption on the cellular level.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Company President, Jim Mackowiak, said plans are underway to expand the Chill Pill line to include new products that are developed with highly bioavailable custom formulations. “The new wave of cannabis consumers value rapid-onset products that are consistent and safe,” he said.
The company’s VP of Business Development, Francis Baczek agrees.
“Chill Pill provides a great delivery system for a consistently accurate dose. We are excited to add new products, expand our team, and bring our improved science and technology to the growth of our business and our brands,” said Baczek. “We have seen tremendous success with the Chill Pill brand because consumers rely upon its products’ accurate dosing, convenience, consistency, and predictable therapeutic effects. Ally Biotech will continue building upon our strong vision for both the medical and adult-use markets, and is well poised to expand the brand successfully.”
Provencio’s long-time business partner and COO of Desert Medical Campus, Pam Donner, concurs. “The company is in good hands with the innovative team at Ally Biotech,” she said.
Mackowiak added that the company has hired key Desert Medical employees and will continue to build a culture of excellence while supporting economic development in Payson, where the current facility is located.
The Chill Pill soft gel cap line includes:
- Day Caps – a sativa-dominant formula.
- Anytime Caps – a formulation that combines sativa and indica.
- Night Caps – an indica dominant formula.
- Anytime Caps + CBD – a 1:1 blend of THC and CBD.
- THC-A – Non-intoxicating symptom relief with no psychoactive effects.
Source: BioSpace
